BeiGene Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

BeiGene wird ein jährliches Gewinn- und Umsatzwachstum von 60.7% bzw. 19% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 63.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.1% betragen.

Wichtige Informationen

60.7%

Wachstumsrate der Gewinne

63.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.1%
Wachstumsrate der Einnahmen	19.0%
Zukünftige Eigenkapitalrendite	14.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	29 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:BGNE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	5,032	223	355	744	22
12/31/2025	4,022	-346	-414	-131	29
12/31/2024	3,239	-859	-786	-604	25
3/31/2024	2,763	-784	-1,566	-902	N/A
12/31/2023	2,459	-882	-1,754	-1,157	N/A
9/30/2023	2,204	-959	-1,853	-1,254	N/A
6/30/2023	1,811	-1,732	-2,283	-1,738	N/A
3/31/2023	1,557	-1,917	-2,298	-1,824	N/A
12/31/2022	1,416	-2,004	-1,966	-1,497	N/A
9/30/2022	1,250	-2,149	-2,144	-1,686	N/A
6/30/2022	1,069	-2,030	-2,016	-1,620	N/A
3/31/2022	877	-1,960	-2,044	-1,660	N/A
12/31/2021	1,176	-1,458	-1,614	-1,299	N/A
9/30/2021	1,062	-1,340	-1,334	-1,123	N/A
6/30/2021	947	-1,327	-1,193	-974	N/A
3/31/2021	863	-1,167	-1,030	-816	N/A
12/31/2020	309	-1,625	-1,510	-1,283	N/A
9/30/2020	266	-1,512	-1,426	-1,218	N/A
6/30/2020	225	-1,394	-1,301	-1,137	N/A
3/31/2020	402	-1,145	-1,093	-920	N/A
12/31/2019	428	-949	-909	-750	N/A
9/30/2019	430	-829	-876	-677	N/A
6/30/2019	434	-665	-747	-544	N/A
3/31/2019	244	-737	-787	-615	N/A
12/31/2018	198	-674	-689	-548	N/A
9/30/2018	158	-505	-344	-260	N/A
6/30/2018	324	-243	-189	-121	N/A
3/31/2018	271	-147	-129	-56	N/A
12/31/2017	238	-93	N/A	13	N/A
9/30/2017	220	-31	N/A	-107	N/A
6/30/2017	N/A	-184	N/A	-138	N/A
3/31/2017	0	-148	N/A	-105	N/A
12/31/2016	1	-119	N/A	-90	N/A
9/30/2016	6	-109	N/A	-80	N/A
6/30/2016	7	-87	N/A	-66	N/A
3/31/2016	8	-69	N/A	-56	N/A
12/31/2015	9	-57	N/A	-40	N/A
9/30/2015	6	-34	N/A	-34	N/A
6/30/2015	11	-29	N/A	-19	N/A
3/31/2015	12	-26	N/A	-11	N/A
12/31/2014	13	-18	N/A	-9	N/A
12/31/2013	11	-7	N/A	4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BGNE wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: BGNE wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: BGNE wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: BGNEDie Einnahmen des Unternehmens (19% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: BGNEDie Einnahmen des Unternehmens (19% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BGNEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.1%).

BeiGene Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2026

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall by 18%

Price target increased to US$290

Recent updates

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

First quarter 2024 earnings released: US$2.41 loss per share (vs US$3.35 loss in 1Q 2023)

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold US$7.5m worth of stock

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Co-Founder notifies of intention to sell stock

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Full year 2023 earnings released: US$8.45 loss per share (vs US$19.43 loss in FY 2022)

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Now 21% undervalued after recent price drop

Beigene, Ltd. Announces Board Changes

Now 22% undervalued after recent price drop

Forecast to breakeven in 2026

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Co-Founder notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Consensus EPS estimates fall by 18%

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

New minor risk - Profitability

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.51 loss in 2Q 2022)

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Shareholder dilution

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma

Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc

Now 20% undervalued after recent price drop

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Announces Presentations At the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

President recently sold US$1.8m worth of stock

President notifies of intention to sell stock

Consensus EPS estimates fall by 18%

Beigene, Ltd. Provides Update Regarding Recent Business Developments

First quarter 2023 earnings: EPS exceeds analyst expectations

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Key Executive exercised options and sold US$15m worth of stock

CFO & Principal Accounting Officer notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations